Messenger RNA vaccines (RNM) became known for their role in the fight against COVID. Years after pandemic, this technology is still subject to the interest of the scientific community, not only for its ability to fight viruses but also as a new hope against very different diseases.
Diseases such as cancer.
A step in the laboratory. Now, an experiment conducted in mice has shown the potential of a new formula against tumors. It is a HRNM -based vaccine capable of boosting the effects of inunotherapy on these rodents. Success is an impulse to a formula that could help us fight various types of cancer.
A name, several diseases. We usually see cancer as a disease that can manifest itself in different parts of our body, but the most complex reality. To the point that it is more convenient to understand this disorder as a variety of diseases, each with its characteristics, but also with specific treatments. That is why finding a universal treatment against cancer is even today, a chimera.
This vision, Explain the responsible team From this new vaccine potential, it applies to the way in which science seeks new treatments of this type. This can be done well causing these vaccines to focus on a “objective” protein expressed in the cancers of multiple people, well adjusting each formula to specific proteins, present in the tumors of each patient.
Third way. The new treatment offers a kind of “third way.” Instead of focusing on proteins of the tumor, what it seeks is to strengthen our immune system, “as if they were going to fight a virus,” says the team.
The formula starts from a previous work, in which a team of the same laboratory created an RNM vaccine capable of “reprogram” the immune system to attack glioblastoma (a brain tumor type particularly aggressive). This vaccine was based on a compound adjusted to the characteristics of the patient’s tumor to be treated. The new formula tries to “universalize” this answer.
“Promising” results. The results when testing the new vaccine in melanoma mice were “promising” even in cases of tumors generally resistant to treatment. As explained by the team, the new formula combines the RNM formulation with a new drug based on immunotherapy called PD-1 inhibitor. This treatment is a monoclonal antibody that seeks, in Team words “Educate” the immune system to make you think that tuum is an external body to eliminate.
The details of the study were Published in an article In the magazine Nature Biomedical Engineering.
The new hope of the MNA. HRNM -based vaccines did not stay in the pandemic and have now become an important focus on oncological research. For now they are just a promise: the positive results in preclinical and clinical trials are hopeful but do not guarantee the arrival of new treatments in the short term. Nor do they guarantee the success of these new drugs.
In Xataka | The patient who has survived 12 different tumors and hides the “holy grail” of the fight against cancer
Image | Tankilevitch polyina
GIPHY App Key not set. Please check settings